Back to search

Article

Safety and immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis patients in Sudan

2020-09-01

Abstract excerpt

Post kala azar dermal leishmaniasis (PKDL) is a chronic, stigmatising skin condition occurring frequently after apparent clinical cure from visceral leishmaniasis. Given an urgent need for new treatments, we conducted a Phase IIa safety and immunogenicity trial of ChAd63-KH vaccine in Sudanese patients with persistent PKDL. LEISH2a ( NCT02894008 ) was an open label three-phase clinical trial involving sixteen adul...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
92b0d3b0-e3ca-59e2-be3f-36d028aa9771
DOI
10.1101/2020.08.26.20180901
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and immunogenicity of ChAd63-KH vaccine in post kala azar dermal leishmaniasis patients in SudanDOI 10.1101/2020.08.26.20180901
Select a neighboring publication to make it the new centre.